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ABSTRACT 
  
  
ABSTRACT 
 
BACKGROUND 
 
Screening  for  fetal  abnormalities  is  necessary  for  early,  timely  
identification  to  take  appropriate  intervention  and  management  to  
achieve  optimal  perinatal  outcome. 
 
Screening  of  fetal  nuchal  translucency  at  10-14  weeks  of  
gestation  identifies  the  fetuses  at  risk  for  chromosomal  
abnormalities,  cardiac defects,  structural  defects,  genetic  
syndromes. 
 
OBJECTIVES 
 
• To  detect  whether  nuchal  translucency  can  be  used  as  early  
screening  tool  to  identify  fetal  abnormalities. 
• To  detect  increased  Nuchal  translucency  in  women  with  
singleton  pregnancy  between  10-14  weeks  of  gestation  and  
its  usefulness  in identifying  the  fetus  at  risk  for  
chromosomal  abnormalities  and  other  defects. 
 
METHODS 
 
We  at  Coimbatore  Medical  College  Hospital  have  undertaken  a  
prospective  clinical  study  in  50  pregnant  women. 
  
Association  of  an  increased  nuchal  translucency  with  fetal  
abnormalities  were  evaluated  in  our  study. 
 
RESULTS 
 
On  statistical  analysis,  our  study  showed  that  there  is  association  
between   increased  nuchal  translucency  and  fetal abnormalities. 
 
INTERPRETATION AND CONCLUSION 
 
This  study  has  given  us  an  insight  to  use  of  fetal  nuchal  
translucency  as  a  screening  tool  to  identify  fetuses  at  risk  for  
chromosomal  abnormalities, cardiac  defects,  and  structural  defects  
at  10-14  weeks  of  gestation.  Thus pushing  prenatal  diagnosis  of  
fetal  abnormalities  to  I  trimester  rather  than  II  trimester,  which  
gives  the  affected  women  an  option  of  early  termination, which  is  
more  acceptable  and  emotionally  less  traumatic  to  the  expectant 
mothers. 
 
KEYWORDS 
Nuchal  Translucency;  Chorion  Villus  Sampling;  Cordocentesis;  
Amniocentesis;  Down’s syndrome;  Aneuploidy;  Fetal Abnormalities;  
Cardiac defects. 
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INTRODUCTION 
  
 INTRODUCTION 
 
One  of  the  important  cause  of  perinatal  death  and  
childhood handicap  is  chromosomal  abnormalities.
1
  The  incidence  
of  significant  chromosomal  abnormalities  and  birth defect  is  3% , 
out of  which  66%  accounts  to  Down’s  syndrome2 ,  25%  of  severe  
mental  retardation  in children  is  due  to  Down’s  syndrome.  The  
frequency  throughout  the  world  is  about  0-13%  of  births.  The  
incidence  in  India  is  1  in  600-700.  Down’s  babies  survives  with  
mental  and  physical  disabilities  and  causes  mental  trauma  to  
family.  Down’s  syndrome  screening  becomes  essential  and   it  is  
done  prenatally  to  reduce  the  live  birth  of   Down’s  babies.3 
Prenatal  screening  has  been  increasing  over  the  past  20  
years  for   Down’s  syndrome  and  other  aneuploidies  with  
amniocentesis,  chorionic  villus  sampling,  cordocentesis.  Previously  
screening  was  done  among  women  of  advanced  maternal  age (age 
> 35 years)  and  those  with  previously  affected  pregnancies.  
Second  trimester  Biochemical  and  sonographic  markers  and  soft   
markers  for  Down’s  syndrome  were  offered  to  women  at  
increased  risk  for  Down’s   syndrome.4  This  combined  approach  
yields  sensitivities  for  screening  to   67-76%   for  a  false  positive  
 rate  of  5%.
5 
 Chromosomal  abnormalities  contribute  to  50%   of  
first  trimester  miscarriages.
8
 
 The  choice  of  definitive  diagnosis  of  aneuploidy  is  limited  
to amniocentesis  which  is  performed  at  15  weeks  of  gestation  at  
the  earliest  and  prenatal  diagnosis  is  made  in  the  second  
trimester.  Furthermore,  amniocentesis  do  not  detect 25%  of  
Down’s  syndrome  and  5%  false  positive  rate  ensures  that  for  
every  single  case  of  Down’s  syndrome  to  be  detected,  60 
amniocentesis  procedures  were  performed.  The  pregnancy  loss  
rate  is  1  in  200  with  amniocentesis  and  about  1  normal  fetus  is  
lost  for  every  3  fetuses  with  Down’s  syndrome  detected.
6 
 First  trimester  screening  includes  Nuchal  Translucency  
measurement,  presence  of  nasal  bone  and  fronto  maxillary  facial  
angle  measurement  Sonographically,  and  biochemical  markers  like  
PAPP-A and  β-HCG,  and  Doppler  study  of  tricuspid  valve  and  
ductus  venosus.7   Also  fetal  anatomy  can  be  systematically  
examined  and  major  structural  anomalies  can  be  detected  at  this  
stage  and  also  helps  in  accurate  pregnancy  dating.  With  these  
screening  facilities,  prenatal  screening  has  moved  from  second  
trimester  to  first  trimester  screening. 
  Thickened  Nuchal  fold  in  Down’s  syndrome  fetus  was  
demonstrated  by  Beryl  Benacerraf  in  1985  after  which  
sonographic  screening  for  aneuploidy  has  become  evident.
9 
 It  was  Dr. Langdon  Down,  100 years  back  has  reported  too  
large  swelling  at  the  back  of  neck  in  affected  fetuses. 
Sonographically  this  swelling  at  the  back  of  neck  is  studied  as  
Nuchal  Translucency  (Down’s  syndrome  was  named  after  his  
name).  NT  measurement  is  best  done  at  10-14  weeks  of  
gestational  age.
10 
 In  addition  to  Down’s  syndrome,  other   
trisomies,  other  chromosomal  defects,  major  cardiac  defects,  
skeletal  defects  and  various  genetic  syndromes  are  associated  with  
increased  Nuchal  translucency.
11 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
  
 AIMS AND OBJECTIVES OF STUDY 
Aim: 
 To  detect  whether  nuchal  translucency  can  be  used  as  an  
early  screening  tool  to identify  fetal  abnormalities. 
Objective: 
 To  detect  increased  Nuchal   translucency in  women  with  
singleton  pregnancy  between  10-14  weeks  of  gestation  and  its  
usefulness  in  identifying  fetus  at  risk  for  chromosomal  
abnormalities  and  other  defects. 
   
  
  
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
  
 REVIEW OF LITERATURE 
Nuchal Translucency: 
 It  is  the  maximum  thickness  of  subcutaneous  translucency 
measured  between  the  skin  and  soft  tissue  overlying  the  cervical  
spine  of  fetus. 
 
Fig. 1: I Trimester Fetus 1 
 
 
Fig 2.Diagrammatic representation of the fetal Nuchal translucency 
    
Fig3.Ultrasound picture of fetal nuchal translucency 
 
 In  many  studies,  cut  off  used  was  3mm  for  abnormal  
nuchal  translucency. It  is  known  that  Nuchal  translucency  
thickness  increases  with  increasing  gestational  age  and  with  
increasing  crown  rump length (CRL).  When  Nuchal  translucency  is  
measured,  it  is  essential  to  correlate  with  gestational  age,  to  
determine  whether  the  given  Nuchal  translucency  thickness  is  
increased.
12-14 
  
Fig. 4: CRL vs. Gestational age (weeks) 
 
Fig. 5: Nuchal Translucency normally increases with gestation (CRL)
 
  Nuchal  translucency  rises  with  increasing  gestational  age.  
The cut  off  on  this  progressive  rise  is  used  as  95
th
  centile  
corresponding  to  gestational  age,  which  results  in  more  sensitive  
and  specific  indicator  for  detection  of  anomalous  fetus.
15, 16 
 
 
Fig. 6: NT vs. CRL 
 
 
 
 
 
 
  In  1992,  Nicolaides KH,  has  been  credited  for  his  
improvements  in  this  field.
17 
 
Kypros H. Nicolaides 
 
 KH Nicolades  et  al, in  1994  conducted  a  study  among  1273  
pregnant  women  with  singleton  pregnancy.  First  trimester  
ultrasound  was  done  at  10-14  weeks  of  gestation.  Association  
with  fetal  aneuploidy  was  noted  with  Nuchal  translucency  greater  
than  or  equal  to  3mm  with  a  sensitivity  of  85%,  specificity  of  
95.9%  and  positive  predictive  value  of  35.5%  with  a  false  
positive  rate  of  5%.18 
 Pandya  et  al,  in  1995  conducted  a  study  among  1763  
pregnant  women.  First  trimester  ultrasound  was  done  at  10-13  
weeks  of  gestation.  Association  with  fetal  aneuploidy  was  noted  
with  Nuchal  translucency  greater  than  or  equal  to  2.5mm  with  a  
 sensitivity  of  75%,  specificity  of  92%  and  a  false  positive  rate  of  
8%.
19
 
 Bewlerg  et  al  in  1995  conducted  a  study  among  1127  
pregnant  women.  First  trimester  ultrasound  was  done  at  8-13  
weeks  of  gestation.  Association  with  fetal  aneuploidy  was  noted  
with  Nuchal  translucency  greater  than  or  equal  to  3mm  with  a  
sensitivity  of  40%,  specificity  of  94%  and  a  false  positive  rate  of  
6.1%.20 
Taipele  et  al,  in 1997  conducted  a  study  among  10,010  
pregnant  women.  First  trimester  ultrasound  was  done  at  10-14 
weeks  of  gestation.   Association  with  fetal  aneuploidy  was  noted  
with  Nuchal  translucency  greater  or  equal  to  3mm  with  a  
sensitivity  of  62%,  specificity  of  99%  and  positive  predictive  
value  of  24%  and  negative  predictive  value  of  100%.
21 
Economides  et  al, in  1998  conducted  a  study  among  2281  
pregnant  women.  First  trimester  ultrasound  was  done  at  11-14 
weeks  of  gestation.  Association  of  fetal  aneuploidy  was  noted  
with  Nuchal  translucency  greater  or  equal  to  the  99
th
 centile  for  
gestational  age  with  a  sensitivity  of  81%,  specificity  of  99%  and  
a  false  positive  rate  of  0.4%.
22 
 Snijders  et  al, in  1998   conducted  a  study  among  127  
pregnant  women  for  assessment  of  risk  with  increasing  maternal  
age.  Study  included  women  of  median  age  of  31 years  with  
singleton pregnancies  and  fetal  nuchal  translucency  measurement  
was  done  at  10-14 weeks  of  gestation  and  reported  a  sensitivity  
of  77%  and  a  false  positive  rate  of  4.4%.
23 
Hafner  et  al, in  1998  conducted  a  study  among  4233  
pregnant  women.  First  trimester  ultrasound  was  done  at  10-14 
weeks  of  gestation.  Association  of  fetal  aneuploidy  was  noted  
with  Nuchal  translucency  greater  than  2.5mm  with  a  sensitivity  
of  65%,  specificity  of  98.5% , positive  predictive  value  of  14.8% 
and  a  negative  predictive  value  of 99.9%  and  a  false  positive  rate  
of  1.5%.
24 
Schwarzler  et  al,   in 1999 conducted  a  study  among  4523  
pregnant  women.  First  trimester  screening  for  fetal  aneuploidy  
and  congenital  heart  defects  by  maternal  age  and  nuchal  
translucency  measurement  at  10-14 weeks  of  gestation  in  
ultrasound  was  done  in unselected   population,  with  a  false  
positive  rate  of  4.7%,  sensitivity   of  76%  in  detecting  fetal   
aneuploidy.
25 
 INCREASED  NUCHAL  TRANSLUCENCY  AND  ITS  
ASSOCIATIONS: 
I. Chromosomal  Defects: 
The  prevalence  of  chromosomal  defects  increases  
exponentially  with  increasing  Nuchal  translucency  
thickness.  Among  these  chromosomal  defects,  Trisomy 21 
(i.e., Down ’s syndrome) accounts  for  50%,  Trisomy 18  or  
13  for  25%,  Turners  syndrome  for  10%,  Triploidy  for  
5%,  other  chromosomal  defects  for  10%.
23
 
II. Fetal  Abnormalities: 
There  is  association  between  increased  NT  and  fetal  
abnormalities  like  aneuploidy , cardiac defects,  skeletal 
defects and  other  defects.  In  chromosomally  normal  
fetuses, with  NT  measurement   <95
th  
percentile,  the  
prevalence  of  fetal  abnormalities  is  1.6%.  It  increases  to  
25%  for  NT  between  the  95
th 
 and  99
th   
percentile  and  
increases  exponentially  thereafter  to  about  45%   for  NT  
of  6.5mm  or  more.
26.27 
 
 
 
 III. Fetal  Death: 
The  prevalence  of  fetal  death  increases  exponentially  
with  increasing   nuchal  translucency  thickness  in  
chromosomally  normal  fetuses.  The  prevalence  is  1.3%  
in  those  with  nuchal  translucency  between  95
th
 and 99
th
 
centile  and  increases  to  about  20%  for  nuchal  
translucency  of  6.5mm  or  more. Death  occurs  by  20 
weeks  of  gestation  in  majority  of fetuses  and  they  even  
progress  to  severe  hydrops.
26, 27
 
 
IV. Developmental  Delay: 
The  prevalence  of  developmental  delay  is  2.4%  in  
chromosomally  and  anatomically  normal  fetuses  with  
increased  nuchal  translucency. 
 
V. Chromosomally  normal  fetuses  with  increased  NT: 
A. Cardiac  defects: In  both  chromosomally  normal  and  
abnormal  fetuses  increased  NT  was  associated  with  
cardiac  defects .(Hyett et al 1997,1999)  In  chromosomally  
normal  fetuses,  the  prevalence  of  major  cardiac  defects  
increases  exponentially  with  NT  thickness  from  16/1000  
 in  those  with  NT  below  the  95th centile,  to  about  1%  
for  NT  of  2.5-3.4 mm,  3%  for  NT  of  3.5-4.4mm,  7%  
for  NT  of  4.5-5.4mm,  20%  for  NT  of  5.5-6.4 mm  and  
30%  for  NT  of  6.5mm  or  more (Souka et al 2004,Hyett et 
al 1997,1999).
28,29,30
 
 
B. Pulmonary  defects: Diaphragmatic  hernia, 
      Cystic  adenomatoid  malformation 
                                                   (Sebire et al  1997)
31
 
 
C. Abdominal  wall  Defect: Cloacal  exstrophy 
          Exomphalos 
           Gastroschisis (Snijders et al 1995)
32
 
 
D. Central  Nervous  System  defects:  
• Acrania / anencephaly 
• Agenesis  of  the  corpus  callosum 
• Craniosynostosis 
• Dandy  walker  malformation 
• Encephalocele 
• Fowler syndrome 
 • Holoprosencephaly 
• Hydrolethalus  syndrome 
• Iniencephaly 
• Joubert  syndrome 
• Macrocephaly 
• Microcephaly 
• Spina  bifida 
• Trigonocephaly C 
• Ventriculomegaly 
E. Neuromuscular  defects: 
• Myotonic  dystrophy 
• Spinal  muscular  atrophy 
F. Body  stalk  anomaly: (Daskalakis et al 1997)
23
 
G. Gastrointestinal  tract  defects: 
• Crohn's  disease 
• Duodenal  atresia 
• Esophageal  atresia 
• Small  bowel  obstruction 
H. Genitourinary  defects: 
• Ambiguous  genitalia 
• Congenital  adrenal  hyperplasia 
 • Congenital  nephrotic  syndrome 
• Hydronephrosis 
• Hypospadias 
• Infantile  polycystic  kidneys 
• Meckel-Gruber  syndrome 
• Megacystis 
• Multicystic  dysplastic  kidneys 
• Renal  agenesis 
I. Skeletal  defects: 
• Achondrogenesis 
• Achondroplasia 
• Asphyxiating  thoracic  dystrophy 
• Blomstrand  osteochondrodysplasia 
• Campomelic  dwarfism 
• Cleidocranial  dysplasia 
• Hypochondroplasia 
• Kyphoscoliosis 
• Limb  reduction  defect 
• Osteogenesisimperfecta 
• Short-rib  polydactyly  syndrome 
• Talipes  equino  varus 
 • Thanatophoric  dwarfism 
• VACTER  association 
J. Metabolic  defects: 
• Beckwith-Wiedemann syndrome 
• GMlgangliosidosis 
• Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase 
deficiency 
• Mucopolysaccharidosis  type  VII 
• Smith-Lemli-Opitz  syndrome 
• Vitamin D  resistant  rickets 
• Zellweger  syndrome 
K. Facial  defect: 
• Agnathia/ micrognathia 
• Facial  cleft 
• Microphthalmia 
• Treacher-Collins  syndrome 
L. Nuchal  defect: 
• Cystic  hygroma 
• Neck  lipoma 
M. Cardiac  defect: 
• Di  George syndrome 
 N. Fetal  anemia: 
• Fetal  anemia 
• Blackfan  Diamond  anaemia 
• Congenital  erythropoietic  porphyria 
• Fanconi  anemia 
• Parvovirus B 19  infection 
• Thalassaemia-α 
 
VI. Genetic Syndromes
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• Achondrogenesis 
• Achondroplasia* 
• Adrenal hyperplasia* 
• Asphyxiating thoracic dystrophy 
• Beckwith-Wiedemann syndrome 
• Blackfan-Diamond anemia 
• Blomstrand  Osteochondrodysplasia 
• Brachmann-Corneliade Lange syndrome 
• Campomelic dysplasia 
• CHARGE association 
• Cleidocranial dysplasia 
 • Dyserythropoietic 
• Erythropoietic Porphyria (Gunther's disease) 
• Fanconi anemia 
• Fowler syndrome 
• Fryn syndrome 
• GM 1-Gangliosidosis* 
• Hydrolethalus syndrome 
• Hypochondroplasia 
• Infantile polycystic kidney disease 
• Joubert syndrome 
• Lymphedema 
• Mucopolysaccharidosis type VII 
• Myotonic dystrophy 
• Nephritic syndrome 
• Noonan syndrome 
• Osteogenesis imperfecta type 11 
• Perlman syndrome 
• Roberts syndrome 
• Smith-Lemli-opitz syndrome 
• Spinal muscular atrophy type 1 
• Stickler syndrome 
 • Thalassaemia-α 
• Thanatophoric dysplasia 
• Treacher  Collins syndrome 
• Trigonocephaly ‘C’ syndrome 
• VACTER association 
• Vitamin D resistent rickets 
• Zellweger syndrome 
 
 
 
 
  
 PATHOPHYSIOLOGY  OF  NUCHAL  TRANSLUCENCY 
 The  various  conditions  associated  with  increased  NT  
suggests  that  there  may  be  several  mechanisms  for  collection  of  
fluid  in  the  skin  behind  the  cervical  spine  and  the  
pathophysiology  is  not  fully  understood. 
Proposed  Theory: 
 Transient  cerebral  hyperperfusion  with  associated  diffusion  
of fluid  across  a  primitive  atlanto-occipital  membrane  in  the  first  
trimester  contributes  to  NT  and  this  might  explain  the  transient  
nature.35 
Other  Theories: 
1. Cardiac  dysfunction 
 There  is  high  association  between  increased  NT  and  
abnormalities  of  heart  and  great  arteries  in  both  
chromosomally  abnormal  and  normal  fetuses,  suggesting  
that  heart  failure  contributes  to  increased  NT. 
In  fetuses,  fluid  collection  behind  the  neck  occurs  much  
like  it  does  in  dependent  ankle  edema  in  later  life.  This  
occurs  partly  because  of  fetal  tendency  to  lie  on  its  back  
and  partly  because  of  the  skin  of  the  neck.
36-39
 
  Any  lymphatic  obstruction  leads  to  an  enlarged  lymph  
sac  and  enlarged  thoracic  duct.  This  exerts  pressure  on  the  
heart  and  displace  the  heart  which  results  in  obstruction  of  
blood  flow  through  the  cardiac  chambers  resulting  in  
abnormal  growth  of  certain  cardiac  structures.   
 
Prevalence  is   
• 0.8/1000  when  NT  is  normal 
• 28.9/1000  when  NT  is  3.5 – 4.4 
• 90.9/1000  when  NT  is  4.5 – 5.4 
• 195.1/1000  when  NT  is  > 5.5 
 
2. Chromosomal  abnormalities 
 Many   of  the  component  proteins  of  the  extracellular  
matrix  are  encoded  on  chromosomes  21,  18 or  13.  
Immunohistochemical  studies,  examining  the  skin  of  
chromosomally  abnormal  fetuses,  have  demonstrated  specific  
alterations  of  the  extracellular  matrix,  which  may  be  
attributed  to  gene  dosage  effects.  
 
 Altered  composition  of  the  extracellular  matrix  may  also  be  
the  underlying  mechanism  for  ↑ fetal NT  in  a  number  of  
genetic  syndromes,  abnormalities  of  fibroblast  growth  factor  
receptors  or  disturbed  metabolism  of  peroxisome  biogeneric 
factor .
40 
 
3. Failure  of  lymphatic  drainage 
Dilatation  of  jugular  lymphatic  sac  results  in  increased  NT.  
Dilatation  of  lymphatic  sacs  results  from  delayed  
development  in  connection  of  lymphatics  with  the  venous  
system  which  interrupts  normal  flow  between  lymphatic  and  
venous   system.  It  may  also  result  from  abnormal  dilation  
of  lymphatic  channels  or  proliferation  of  the  lymphatic  
channels.41 
 
4. Venous  congestion  in  head  and  neck 
Constriction  of  fetal  body  or  chest  resulting  from  various  
condition  leads  to  venous  congestion  of  head  and  neck.
43 
 
 
 
 5. Fetal  anemia  and  hypoproteinemia  
Fetal  anaemia  resulting  from  genetic  causes,  infection,  can  
present  with  heart  failure  which  can  present  with  increased  
fetal NT.
43 
 
6. Neuromuscular  abnormalities 
Causes  poor  breathing  and  body movements,  which  may  
lead  to  fluid  accumulation  as  that  happens  in  peripheral  
edema  e.g., arthrogryposis – Contractures  and  flexion-
deformaties.
41 
 
7. Fetal  infection 
Increased   NT  is  associated  with  Parvovirus B19.  Torch  
group  of  organisms  have  less  association  with  increased  
nuchal  translucency.  In  fetal  infections,  there  is  suppression  
of  hemopoiesis  due  to  myocardial  dysfunction,  fetal  anemia  
which  leads  to  increased  NT. 
 
 
 
 
 Transient  nature  of  Nuchal  Translucency   between 10-14 weeks 
 The  fetal  lymphatic  system  is  developing  between  10-14 
weeks  of  gestation  and  the  peripheral  resistance  of  the  placenta  
is  also  high.  So  the  excess  fluid  accumulates  behind  the  neck  
leading  to  increased  NT.  After  14 weeks  of  gestation,  the  
lymphatic  system  is  well  developed  to  drain  away  the  excess  
fluid  to  placental  circulation.  After  this  period,  fetal  abnormalities  
causing  fluid  accumulation  will  be  corrected  by  itself  and  goes  
undetected  by  measuring  NT.
30
 
Reason  for  selecting  up  to  14  weeks  for  NT: 
1. To  provide  women  safe  and  earlier  termination  when  fetus  
is  affected 
2. The  incidence  of  increased  NT  is  lower  at  14-18 weeks  
than  at  < 14 weeks  of  gestation  in  affected  fetus.
45, 46 ,47
 
3. Fetus  will  be  in  horizontal  position  at  10-14 weeks  of  
gestation,  ideal  position  for  taking  measurement  with  a  
success  rate  of  98% - 100%.  It  is  difficult  to  obtain  
appropriate  image  beyond  14 weeks  as  the  fetus  will  often  
be  in  vertical  position. 
 
 Reason  for  selecting  10 weeks  as  lower  limit: 
1. CVS  was  the  diagnostic  test  before.  CVS  done  before             
10 weeks  was  associated  with  transverse  limb  reduction  
defects. 
2. Fetal  structures  are  visualized  after  10 weeks,  any  fetal  
abnormalities  can  be  diagnosed  with  NT scan. 
 
 
  
 METHODS  OF  MEASURMENT  OF  NUCHAL 
TRANSLUCENCY(NT): 
 NT  can  be  measured  by  transabdominal  or  transvaginal  
ultrasound.  Scan  should  be  done  by  trained  Radiologist.  The  
equipment  must  be  of  good  quality,  with  5MHz  transabdominal  
probe  or  8MHz  transvaginal  probe.  It  should  have  a  video loop 
junction  to  1  decimal  point.  NT  scan  should  be  done  for  at least   
10-20  minutes.  NT  measurement  should  be  tried  for  atleast  20  
minutes  before  abandoning  the  procedure.  CRL  should  be  
correctly  measured  with  fetus  in  proper  sagittal  view  of  spine.
53
 
1. Fetus  is  examined  in  mid  sagittal  section,  either  facing  
towards  or  away  from  the  transducer  with  thalamus,  
medulla  oblongata  and  pons  are  visible. 
2. Fetus  must  be  in  neutral  position  especially  the  neck  for  
NT  to  be  measured.  Standard  Techniques  for  NT  
measurement  is   the  Fetal  medicine  foundation (FMF) 
criteria. 
When  the  fetal  neck  is  hyperextended  NT  value  increases  
by  0.6mm  and  when  it  is  flexed  the  NT  value  decreases  
by 0.4mm.
54,55
 
  
 
 
Fig. 7: Nuchal translucency measurement that meets 
Fetal Medicinal Foundation criteria (t=thalamus, mo=medulla 
oblongata, p=pons). The correct caliper placement is “on-to-on”. 
 
 
 
Fig.8 Magnification  is  too  small  for  accurate  measurement  of  NT 
 
 
  
 
Fig.9 Neck  is  hyperextended, not correct  for  measuring  NT 
 
 
 
Fig.10 Neck  is  too  much  flexed, not suitable  for  measuring  NT 
 
3. The  gestational  age  should  be  10-14 weeks  and   fetal  CRL  
should  correspond  to  38-84mm. According  to  fetal  medicine  
update – gestational  age  should  be  11-13+6 weeks  and  fetal  
CRL correspond  to   45-84mm.
56, 57
 
 4. Fetal  image  should  occupy  75%  of  the  screen.  Fetal  image  
should  include  only  the  fetal  head  and  upper  thorax.
58
 
5. Magnification  of  the  image  should  be  as  large  as  possible,  
so  that  slight  movement  of  calipers  produces  only  0.1mm  
change  in  measurement.
58 
Caliper  should  be  placed  correctly  
i.e., on  inner  border  of  nuchal  fold  and  perpendicular  to  
long  axis  of  the  fetal  body  i.e.,  “on  to  on”  caliper  
placement  only        cross-shaped (+)  caliper  is used. 
 
 
Fig. 11: Correct placement of calipers 
6. The  fetal  skin  and  amnion  should  be  distinguished  carefully  
since  both  structures  appear  as  thin  membranes.  They  are  
distinguished  when  there  is  spontaneous  fetal  activity,  the  
fetus moves  away  from  amniotic  membranes.  This  is  also  
achieved  when  the  mother  coughs  or  mother’s  abdomen  is  
tapped.
2
 
 7. Measurement  of  maximum  thickness  of  subcutaneous  
translucency  between  the  skin  and  the  soft  tissue  overlying  
the  cervical  spine  is  taken.  Multiple  measurement  are  taken  
and  maximum  one  is  recorded  to  be  more  accurate.
2
 
 
 
 
 Fig.12 Maximum  measurement  of  NT  to  be  taken. 
 
8. In  5%  of  cases  umbilical  cord  surrounds  the  fetal  neck  and  
this  produces  falsely  increased  NT.  In  this  case,  NT  
measurements  above  and  below  the  cord  levels  are  
different,  it  is  best  to  use  the  average  of  those  two  
measurements. 
 
  
 
Fig. 13: Umbilical  cord  surrounds  the  fetal  neck  that  disrupts  NT 
measurement. 
 
Pitfalls  in  measurement: 
• Loose  amnion  that  can  be  mistaken  for  nuchal  skin  edge 
• Nuchal  cord 
• Encephalocele 
• An  amniotic  band 
Methods  to  avoid  Bias: 
• To  wait  for  fetal  activity  to  differentiate  the  amnion   from  
fetal  skin 
• In  nuchal  cord  - colour  Doppler  may  be  helpful 
• Adequate  magnification  distinguishes  fetal  skin  and  amniotic  
membrane 
 Per-requisites: 
1) Appropriate  training 
2) High  motivation 
3) Strict  adherence  to  FMF  technique  for   measurement 
Implementation  of  NT  screening  in  routine: 
NT – Calculation  of  patient-specific  risk 
• Every  fetus  has  its  own  risk  to  have  chromosomal  defect.  
To  calculate  the  individual  risk,  it  is  necessary  to  take  into  
account  the  background  or  a  “prior risk”  that  depends  on  
the  maternal  age  and  gestation  and  it  is  multiplied  by  a  
series  of  factors,  resulting  from  the  series  of  screening  tests  
carried  out  during  the  course  of  the  pregnancy. 
 
• Dividing  the  percentage  of  chromosomally  abnormal  fetuses  
by  the  percentage  of  normal  fetuses  gives  the  likelihood  
ratio  for  a  given  sonographic/biochemical  measurement. 
 
 
 
 • Prospective  studies  were  conducted  among  2,00,000  
pregnancies,  in  which  more  than  900  fetuses  were  with  
Down’s  Syndrome.  This  study  proved  that  NT  measurement  
can  identify  more  than  75%  of  fetuses  with  Down’s  
Syndrome  with  a  false   positive  rate  of  5%.
64
 
 
  
 OTHER  SCREENING  MODALITIES  FOR  CHROMOSOMAL  
DEFECTS 
1. Maternal  Age:  
In  1909,  shuttle  worth  was  the  first  to  notice  that  mother’s  
of  Down’s  child  were  of  old  age  than  average.  
Chromosomally   abnormal  fetuses  are  more  likely  die  in  
utero  than  normal  fetus,  so  the  risk  decreases  with  
gestational  age  and  increase  with  increasing  maternal  age. 
 
Fig. 14: Maternal age related for chromosomal abnormalities 
Perviously  screening  for  Down’s  Syndrome  was  based  on  the  
advanced  maternal  age.  When  screening  conducted  on  this  basis  
only  30%  of  down’s  babies  was  detected.
34 
 Estimated  risk  for  trisomies  21,  18,  and  13  in  relation  to  
maternal  age  and  gestation
68 
Maternal 
Age 
(Years) 
Trisomy 21 Trisomy 18 Trisomy 13 
Gestation (wks) Gestation (wks) Gestation (wks) 
 12 16 20 40 12 16 20 40 12 16 20 40 
20 1068 1200 1295 1527 2484 3590 4897 18013 7826 11042 14656 42423 
25 946 1062 1147 1352 2200 3197 4336 15951 6930 9778 12978 37567 
30 626 703 759 895 1456 2013 2869 10554 4585 6470 8587 24856 
31 543 610 658 776 1263 1825 2490 9160 3980 5615 7453 21573 
32 461 518 559 659 1072 1549 2114 7775 3378 4766 6326 18311 
33 383 430 464 547 891 1287 1755 6458 2806 3959 5254 15209 
34 312 350 378 446 725 1047 1429 5256 2284 3222 4277 12380 
35 249 280 302 356 580 837 1142 4202 1826 2576 3419 98J’6 
36 196 220 238 280 456 659 899 3307 1437 2027 2691 7788 
37 152 171 185 218 354 512 698 2569 1116 1575 209 6050 
38 117 131 142 167 272 393 537 1974 858 1210 1606 4650 
39 89 100 108 128 208 300 409 1505 654 922 1224 3544 
40 68 76 82 97 157 227 310 1139 495 698 927 2683 
41 51 57 62 73 118 171 233 858 373 526 698 2020 
42 38 43 46 55 89 128 175 644 280 395 524 1516 
 
 
  
 
Fig. 15: Maternal age related for trisomy 21 at 12 weeks of gestation and the  
effects of fetal nuchal translucency thickness 
 
In  1990,  screening  for  Trisomy  21,  with  maternal  age  was  
combined  with  fetal  NT  thickness  at  10-14  weeks  of  
gestation.   This  improved  the  detection  rate  to  75%  of  
affected  fetuses  with  Trisomy 21. 
 
 
 
 2. Other  ultrasound  markers  in  I  trimester: 
In  the  I  trimester,  presence  of  nasal  bone,  measurement  of   
fronto  maxillary  facial  angle,  Doppler  study  of  tricuspid  
valve  and  ductus  venosus,  any  major  structural  anamolies   
are  performed. 
Nasal  Bone: 
Nasal  bone  is  visualized  by  ultrasound  done  in  first  
trimester  and  the  position  of  fetus  to  visualize  the  nasal  
bone  is  same  as  NT  measurement.  The  face  of  
transducer  is  parallel  to  long  axis  of  the  nasal  bone  and  
the  skin  over  nasal  bridge.  
 
 The  skin  over  the  nasal  bridge  and  the  nasal  tip  
visualized  as  echogenic  lines.  The  nasal  bone  present  
within  the  substances  of  the  nasal  bridge  is  also  seen  as  
echogenic  line.  When  nasal  bone  is  present,  “equal sign”  
is  present. 
  
Fig. 16: (16a) The nasal bone (NB) is resent (solid arrow). The NB and the 
echogenic skin over the nasal bridge (open arrow) create then so called “equal 
sign”.  
 
 Fig.(16b)Nasal bone is absent (note absence of the “equal sign”. Only a single 
echogenic line representing the echogenic skin over the nasal bridge (open 
arrow) is present. (T=thalamus, BS=brain stem) 
 
 Appearance  of  nasal  bone  is  based  on  the  facial  
features  in  individuals  with  Down’s  syndrome.  There  may  
be  difference  in  size  or  degree  of  ossification  of  nasal  
bone  or  the  nasal  bone  may  be  absent.  This  may  be  due  
to  changes  in  connective  tissue  that  happens  in  Trisomy 21. 
 Nasal  bone  is  absent  in  approximately  60%  of  fetuses  
with  Trisomy 21  and  1-2.5%  of  euploid  fetuses.  NB  
evaluation  when  combined  with  first  trimester  screening  led  
to  increased  detection  rate  to  90%.   
Frontomaxillary  facial  angle (FMF angle): 
 The  fetus  is  in  the  same  position  of  NT  measurement  
and  FMF  angle  is  measured  using  Fetal  Medicine  
Foundation  criteria.  First  ray  is  drawn  along  the  upper  edge  
of  hard  palate,  apex  is  on  the  anterior  aspect  of  maxilla,  
second  ray  is  from  apex  upwards  resting  on  echogenic  line  
beneath  the  skin  (non-calcified metopic suture).  FMF  angle  
is  acute  in  normal  conditions. 
 
  
 
 
Fig. 17A and B: Frontomaxillary angle measurement that meets Fetal Medicine Foundation 
criteria (t=thalamus, mo=medulla oblongata, p=pons). Note the absence of the frontal process 
of the maxilla between the hard palate and the nasal bine, which helps to assure that plane of 
insonation is precisely in the midline. (A) The frontomaxillary angle is acute and within 
normal limits: (B) The frontomaxillary angle is obtuse and is above the normal range 
 
 Flat  faces  is  a  common  dysmorphic  feature  in  
Down’s  babies  due  midface  hypoplasia  resulting  from  
abnormal  connective  tissue.  This  flatness  of  the  face  is  
assured  by  FMF  angle.  
 
When  performed  on  3D  volumes  demonstrated  that  
70%  of  Down’s  syndrome  fetuses  had  FMF  angle  
measurement  that  was  above  95th  percentile  of  the  normal  
population.  In  2D  technology,  this  rate  falls  to  50%.  FMF  
angle  is  independent of   NT  measurement,  nasal  bone  and  
serum  biochemistry. 
Intracranial  Translucency (IT) : 
 Intracranial  Translucency  is  another  sonographic  
marker  of  fetal  anamoly  especially  spina  bifida. IT  is  
measured  at  11-13 weeks  of gestation,  with  the  fetus  in  mid  
sagittal  view  and  in  neutral   position  and  magnification  
same  as  in  NT  measurement . 
 
  
 
Fig 18(A). Fetal  brain  structures  in  mid  sagittal  view  and  4
th
 
ventricle  represents  the  Intracranial  Translucency. 
 
 
Fig 18(B). Intracranial  Translucency  measurement. 
 
 
  Intracranial  Translucency  is  the  measurement  of  the 
fourth  cerebral  ventricle  between  the  brain  stem  and  the  
choroid    plexus.  IT  is  measured  as  anteroposterior  diameter.  
In spina  bifida,  there  is  caudal  displacement  of  hindbrain  
which  compresses  the  fourth  ventricle.  This  space  which  
was  measured  as  IT  will  be  obliterated  due  to  this  
displacement.  If  IT  is  not  measurable,  the  fetus  is  at  risk  
of  spina  bifida  especially  open  spina  bifida.      
Doppler  evaluation  of  fetal  blood  flow  as  markers  for  
aneuploidy: 
There  is  high  interventricular  pressure  at  any  cardiac  
volume  due  to  lower  compliance  of  fetal  myocardium.  
Placental  vascular  resistance  is  high  in  early  pregnancy  
causing  additional  strain  on  the  heart.  Any  abnormalities  of  
cardiac  structures  or  performance  leads  to  detectable  
changes  in  blood  flow  through  Tricuspid  valve  and  Ductus  
venosus. 
 
 
 
 Tricuspid  valve  regurgitation: 
In  Trisomy 21,  there  is  increased  prevalence  of  
tricuspid  valve  regurgitation  may  be  due  to  decreased  
number  of  myocytes  with  decreased  orientation  of  the  
myocytes  and  abnormal  connective  tissue.  It  may  also  
result  from  dilatation  of  right  ventricle  with  dilatation  of  
tricuspid  valve  annulus  or  connective  tissue  abnormality  of  
the  valve  itself. 
 
Fig 19A and B. Evaluation of the flow across the tricuspid valve (TCV) using 
Doppler; (A) Normal flow pattern across the TCV with no regurgitant flow 
during ventricular systole (VS); (B) Abnormal flow pattern across the TCV 
with regurgitant flow (R) present during ventricular systole (VS) 
 
 
 Normal  tricuspid  valve  waveform  shows  Biphasic  
pattern  of  blood  flow  into  the  right  ventricle.  First  wave  is  
the  increase  in  forward  flow  at  the  beginning  of  ventricular  
diastole  followed  by  a  decrease.  Second  wave  is  increase  in  
flow  corresponding   to  atrial  systole . Any  flow  across  the  
tricuspid  valve  during  ventricular  systole  represents  
regurgitation.  In  tricuspid  valve  regurgitation  flow  across  
the  valve  must  be  atleast  30%  of  ventricular  systole  and  
the  peak  velocity  of  regurgitation  jet  must  be  more  than  
60cm/sec. 
At  11-14  weeks  of  gestation,  prevalence  of  tricuspid  
valve  regurgitation  in  Trisomy 21  fetuses  is  55%,  in  euploid  
fetuses  it  is  1%,  in  Trisomy 18  fetuses  it  is  33%,  in  
Trisomy 13  it  is  30%  and  monosomy   38%. 
Ductus  venosus – Reversed  A  wave: 
Normal  waveform  demonstrates  forward  flow  
throughout  the  cardiac  cycle  with  two  adjoining  peak  of  
increased  flow  in  ventricular  systole  and  diastole,  and  a  
decreased  flow  during  atrial  systole  but  forward  flow  is  
maintained.  ‘A’  wave  represents  atrial  systole. 
  
Fig 20A and B. Evaluation of ductus venosus (DV) flow using Doppler 
(uv=hepatic portion of the ublical vein) (A) Normal DV flow pattern with 
antegrade flow during the entire cardiac cycle, including during the atrial 
contraction (a-wave); (B) abnormal DV flow pattern with reversed flow 
during atrial contraction(a-wave). 
 
Reversed  ‘A’  wave  in  ductus  venosus  Doppler  occurs  
in  aneuploidies  which  results  from  decreased  compliance  of  
ventricular  wall  rather  than  ventricular  dilation.  
Abnormalities  in  ‘A’  wave  are  also  associated  with  
increased  risk  of  cardiac  anomalies  and  it  is  followed  up  
by  second  trimester   target  scan  and  fetal  echocardiography. 
 The  prevalence  of  reversed  flow  of  ‘A’  wave  in  
Trisomy 21  is  66%,  Trisomy 18  is  58%,  Trisomy 13  is  
55%,  monosomy  is  75%  and  in  euploid  is  3%. 
 
 Fetal  Heart  Rate (FHR) screening  for  aneuploidy: 
Aneuploidy  fetuses  have  different  heart  rates  at  first  
trimester  compared  with  normal  fetuses.  In  Trisomy 21,  
14%  of  fetuses  have  fetal  heart  rate >95
th 
 percentile.  In  
Trisomy 13  and  monosomy,  fetus  have  FHR > 95th percentile  
in  69%  and  53%  respectively.  In  Trisomy 18  and  triploidy,  
fetuses  tend  to  be  bradycardiac. FHR  needs  to  be  adjusted  
for  gestational  age  when  included  in  first  trimester  
screening. 
Screening   for  fetal  structural  anamolies  in  I  trimester: 
Structural   anamolies  like  holoprocencephaly,  
diaphragmatic  hernia,  atrioventricular  septal  defect,  
omphalocele,  megacystis  are  associated  with  aneuploidies  
and  are  detectable  in  I  trimester  by  ultrasonogram. 
3. Maternal  serum  screening  in  I  trimester: 
Now  a  days  it  is  noted  that  PAPP-A  (Pregnancy  
associated  Plasma   Protein – A)  is  probably  the  best  marker  
for  Down’s  syndrome  in  I  trimester. 
 PAPP-A  is  a  pregnancy  specific  glycoprotein  
produced  by  the  trophoblast.  It  becomes  detectable  in  
maternal  serum  from  28  days  after  conception.  It  is  low  in  
Down’s  syndrome  and  other  trisomies. 
Free  β-HCG  is  another  biochemical  marker   used  in  
Down’s  syndrome.  It  is  elevated  in  Trisomy 21  and  other  
trisomies.  
• Maternal  age + PAPP-A  »  detects  71%  cases  of  
Down’s  syndrome 
• Maternal  age + PAPP-A + free β-HCG  »  detects  85-
90%  of  Down’s  syndrome 
I  trimester  screening  for  aneuploidy  using  multiple  
ultrasound  markers – Risk  assessment  by  Fetal  Medicine 
Foundation: 
 This  risk  assessment  is  done  to  categorize  the  women  
at  risk  for  aneuploidy  into  high  risk,  intermediate  risk  and  
low  risk  in  the  first  trimester  itself. 
   
 
 This  approach  includes  the  following  parameters 
− Maternal  Age 
− NT  measurement 
− Free  β-HCG 
− PAPP-A  level 
Includes  3  risk  categories  depending  on  the  risk  of       
Trisomy 21 
1. High  Risk: 
 Women  whose  risk  of  trisomy 21  is  1:50  or  greater.  
They  are  offered  invasive  testing  like  amniocentesis / 
chorion  villous  sampling 
2. Intermediate  risk: 
• Women  with  risk  1:51  to  1:1000 
• They  are  assessed  with  additional  markers  like  Nasal  
bone,  Doppler  study  of  tricuspid  valve  and  Ductus  
venosus. 
• After  additional  assessment,  if  they  fall  in  high  risk  
»  invasive  testing  is  done. 
• If  they  fall  in  low  risk  »  followed  up  with  targeted  
ultrasound  at  20 weeks 
 3. Low  Risk:  
• Women  with  risk  less  than  1:1000 
• No  testing  is  done 
• Followed  up  with  targeted  scan  at  20  weeks 
OSCAR (One Stop Clinic For Assessment of Risk)
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 Recently,  maternal  age  was  combined  with  fetal  NT  and  
maternal  Serum  biochemistry  (free β HCG +PAPP-A)  in  I  trimester  
to  identify  about  85-90%  of  affected  fetus.  Furthermore, the  
development  of   new  methods  of  biochemical  testing,  within  30  
minutes  of  taking  a  blood  sample,  made  it  possible  to  introduce  
One - Stop  Clinic  for   Assessment  of  Risk. 
 
 
 
 
 The  nasal  bone  will  not  visible  in  I  trimester  scan  in  60-
70%  fetuses  with  Trisomy 21.  So  I  trimester  scan  along  with  
serum  Biochemistry  will  detect  more  than  95%  Trisomy 21.
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Screening 
Ultrasound 
Biochemistry 
Chorionic villus sampling Counseling 
 4 Invasive  testing  in  first  trimester: 
 Invasive  testing  available  in  first  trimester  are  
Chorionic  villus  sampling (CVS)  and  Celocentesis. 
Chorionic  villus  sampling (CVS): 
 CVS  is  performed  either  transcervically  or  
transabdominally.  It  is  an  invasive  procedure  used  for  
fetal  karyotyping  and  DNA  analysis  prenatally.  
Previously  CVS  was  done  at  7-8 weeks  which  had  
higher  incidence  of  limb  defects.  Now  CVS  is  done  at  
or  after  10 weeks  to  reduce  the  fetal  defects  caused  by  
the  procedure. 
Indication: 
 CVS  is  done  for  mainly  for  the  following  indications. 
 1.Monogenic  disorders- Thalassemia 
             Cystic  fibrosis 
             Hemophilia 
             Duchene  muscular  dystrophy  
             Becker’s  muscular  dystrophy 
 2.Metabolic  disorders-  Mucopolysacharidosis 
           Lipidosis 
           Aminoacid  metabolic  disorders 
               Carbohydrate  metabolic  disorders 
 Technique: 
 CVS  is  performed  either  transcervically  or  
transabdominally. 
Transcervical  CVS: 
 It  is  performed  with  polyethylene  catheter  or  biopsy  
forceps  under  the  guidance  of  real  time  ultrasound.  
Pregnant  women  in  lithotomy  position,  under  strict  
aseptic  precaution , the  aspiration  catheter  or  biopsy  
forceps  is  advanced  transcervically  to  obtain  the  sample.  
A  sample  of  5-40mg  is  sufficient  for  prenatal  diagnosis. 
 
 
                  Fig 21. Transcervical  chorionic villus sampling 
  
 Transabdominal  CVS: 
 It  is  performed  with  aspiration  needle  either  by  the  
“Two  needle”  or  the  “free  hand” (single  needle)  
technique.  Pregnant  women  in  supine  position  under  
strict  aseptic  precaution , the  aspiration  needle  is  used  to  
aspirate  5-40mg  of  tissue.  This  is  technically  similar  to  
mid  trimester  amniocentesis.  
 Transabdominal  CVS  will  be  difficult  in  posterior  
placental  site,  potential  bowel  adhesions,  retroversion  and  
retroflexion  of  uterus  which  needs  transcervical  approach. 
 
 
       Fig 22. Transabdominal  chorionic  villus  sampling. 
 
  CVS  allows  early  diagnosis.  Genetic  results  will  be  
available  within  hours  by  direct  preparation  of  the   
cytotrophoblast  layer  or  within  3-7  days  by  tissue  
culture  of  chorionic  villus  mesenchymal  core. 
Complications: 
• CVS  done  before  10 weeks  led  to  fetal  limb  
reduction  defects.  This  is  reduced  by  performing  
CVS  at  or  after  10 weeks of  gestation.  
• Fetal  loss  is  another  complication,  but  it  is  similar  
to  that  of   amniocentesis. 
• Vaginal  bleeding  
• Post  CVS  infections 
 Celocentesis: 
 This  is  another  method  of  invasive  procedure  for  
screening  fetal  anamolies  screening.  It  is  done  at  7-8 
weeks  of  gestation  which  is  done  earlier  than  CVS.  
Indications: 
• To  determine  fetal  sex 
• β  thalassemia 
• Sickle  cell  anemia 
 • Marfans  syndrome 
• Paternity  testing 
Technique: 
 Celomic  cavity  occupies  most  of  the  gestational  sac  till       
9 weeks  of  gestation.  Celocentesis  is  performed  transvaginally  by  
inserting  a  20G  needle  into  the  celomic  cavity  under  ultrasound  
guidance.  1-2 ml  of  the  celomic  fluid  is  aspirated  and  sent  for  
biochemical  analysis  and  cytogenetic  studies. 
Complications: 
• Fetal  loss 
• Fetal  limb  reduction  syndrome 
• Fetal  oromandibular  hypoplasia 
• Intracelomic  hemorrhage 
Maternal  Serum  Screening  in  II  trimester: 
A  new  method  of  screening  was  introduced  in  1980  
that  considers  maternal  age  and  the  concentration  of  various  
fetoplacental  biochemical  products  in  the  maternal  
circulation.
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 The  maternal  serum  concentration  of  AFP  (α Fetoprotein),  
unconjugated  estriol (UE3), human   chorionic  
gonadotrophin(HCG)  (total and free β)  are  measured  at 16 
weeks  of  gestation.  In  Trisomy 21  β-HCG  will  be  elevated  
UE3  and  AFP  will  be  decreased.  These  3  serum  markers  
are  used  in  triple  test.  Another   marker  Inhibin A  is  used  
along  with  triple  test  which  is  elevated  in  aneuploidy.  This  
concept  is  used  to  identify  the  high  risk  group. 
 
Detection  Rate  of 
Trisomy21 
MSAFP 36% 
Dual Test – MSAFP + Free β HCG 58% 
Triple Test- unconjugated Estriol + β-HCG + AFP 67% 
                                           ↓              ↑            ↓         
 
Quad Test - Triple test + Inhibin A (↑)71,72 70% 
 
 
 
 
 Invasive  testing  in  II  trimester: 
 Amniocentesis  and  Cordocentesis  are  invasive  
procedures  done  in  II trimester. 
Amniocentesis :    
 Amniocentesis  is  the  invasive  testing  available  for  
screening  in  the  II  trimester  and  it  is  a  safe  technique  
among  the  invasive  procedures.  Amniocentesis  was  first  
done  therapeutically  for  polyhydramnios  to  drain  excess  
amniotic  fluid.  Later  it  was  used  for  Rh  isoimmunisation, 
then  for  sex  identification  and  now  it  is  used  as  a  
screening  test  for  fetal  chromosomal  abnormalities  and  other  
congenital  defects. 
Indications: 
• Fetal  karyotyping 
• Genetic  diseases-β  thalassemia 
        Cystic  fibrosis 
        Hemophilia 
        Congenital  adrenal  hyperplasia 
       Fetal  lung  maturity 
 
 • Congenital  fetal  infections-TORCH  
• Severity of  fetal  hemolytic  anaemia  in  Rh  
isoimmunisation 
• Fetal  therapy  in  twin  oligohydramnios - 
polyhydramnios  sequence  and  twin-to-twin  
transfusion  syndrome 
• Amnioinfusion  in  oligohydramnios 
• Infusion  of  drugs  into  amniotic  cavity 
 
          Fig 23. Amniocentesis under  ultrasound  guidance. 
 
  
 Technique: 
 Amniocentesis  is  performed  at  15-18 weeks  of  gestation.  It  
is  performed  under  strict  aseptic  precaution  with  22G  needle  
under  direct  ultrasound  guidance.  Detailed  ultrasound  examination  
of  the  fetal  anatomy,  amniotic  fluid  volume,  placental  location,  
uterine  abnormality  and  adnexal  masses  are  done  prior  to  the  
procedure.  The  site  of  entry  of  the  needle  must  be  away  from  
the  face,  umbilical  cord  and  placenta.  20 ml  of  the  fluid  is  
aspirated  and  sent  for  cytogenetic  study.  Repeat  ultrasound  is  
done  to  confirm  fetal  cardiac  activity  and  absence  of  
intraamniotic  bleeding.  
 In  twin  pregnancies  double  amniocentesis  is  done  with  
either  one  or  two  separate  22G  needles.  When  two  needles  are  
used, they  are  inserted  sequentially  in  each  sac  and  20ml  of  
amniotic  fluid  is  aspirated  from  each  sac. When  one  needle  is  
used,  the  needle  is  entered  into  the  proximal  sac  near  the  
insertion  of  the  dividing  membrane  and  20ml  of  amniotic  fluid  is  
aspirated.  Then  the  needle  is  advanced  through  the  second  sac  
under  direct  ultrasound  guidance  and  20 ml  of  amniotic  fluid  is  
aspirated  from  the  second  sac. 
 Complications:   
• Fetal  loss 
• Fetal  injury 
• Preterm  delivery 
• Rh  isoimmunisation  from  fetomaternal  hemorrhage 
• Neonatal  respiratory  distress  syndrome  due  to  
postprocedure  oligohydramnios 
• Orthopedic  abnormalities  due  to  oligohydramnios 
• Vaginal  spotting  
• Leakage  of  amniotic  fluid. 
Cordocentesis / Percutaneous Umbilical Blood Sampling(PUBS): 
 Cordocentesis  is  done  transabdominally  under  ultrasound  
guidance.  This procedure  has  been  limited  by  CVS  and  
amniocentesis.  PUBS  has  been  done  mostly  for  confirmation  of  
abnormal  findings  in  amniocentesis  and  CVS. 
Indications: 
• Rh  isoimmunisation 
• Hydrops  of  unknown  origin 
• Fetal  infections 
 • To  inject  drugs  into  fetal  circulation 
• For  blood  transfusion  in  fetal  anaemia 
 
 
    Fig 24. Transabdominal uitrasound guided fetal blood sampling. 
Technique: 
 A  detailed  ultrasound  examination  of  the  fetus,  placenta,  
uterus  are  done. Under  strict  aseptic  precaution,  with  ultrasound  
guidance,  a  22G  needle  is  introduced  either  trans-placentally  in  
case  of  anterior  placenta  or  through  the  amniotic  cavity  in  case  
of  posterior  placenta  targeting  the  umbilical  vein  proximal  to  the  
insertion  of  umbilical  cord  into  the  placenta. The  intrahepatic  
portion  of  the  umbilical  vein, the  left  portal  vein  and  the  right  
ventricle  have  been  used  to  obtain  fetal  blood  sample. 
  4ml  and  6ml  of  fetal  blood  should  be  withdrawn  for  
sampling  during  the  second  and  third  trimester  respectively. The  
cord  puncture  site  should  be  followed  up  sonographically  for  10 
minutes  for  bleeding  or  hematoma  and  fetal  heart  rate  for  30-60 
minutes  after  the  procedure. 
Complications: 
• Fetal  loss 
• Bleeding  at  puncture  site 
• Umbilical  cord  hematoma 
• Transient  fetal  bradycardia 
• Fetomaternal  blood  transfusion 
• Uterine  contractions 
•   Chorioamnionitis  
 
 
 
 
 
 
 Method  of  Screening
34 
DR% of Down Syndrome 
Material Age (MA) 30% 
MA + Material serum Biochemistry at 15-18 weeks 50-70% 
MA+ Fetal NT 70-80% 
MA+ Fetal NT +serum free βHCG+PAPP-A at 10-
14 weeks 
85-90% 
MA +Fetal nasal bone + Fetal NT 90% 
MA + Fetal NT+ NB+ Maternal serum  
Free βHCG +PAPPA at 10-14 weeks 
95% 
II  Trimester  Ultrasonography
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 Benacerraf’s  scoring  system  for  Down  Syndrome: 
Findings Score 
Major  Anomaly 2 
Nuchal  fold ≥ 6mm 2 
Hyperechoic  bowel 1 
Echogenic  intracardiac  focus 1 
Pyelectasis ≥ 4mm 1 
Short  femur 1 
Short  humerus 1 
Note: A  score  of  ≥ 2  warrants  an  invasive  testing. 
 
 Central Nervous System 
• Holoprocencephaly 
• Dandy  walker  Syndrome 
• Agenesis  of  corpus  callosum 
• Ventriculomegaly 
• Choroid  plexus  cyst 
• Dilated  cisterna  magna 
 
Cardiovascular system 
• VSD 
• ASD 
• Tetralogy  of  Fallot’s 
• Endocardial  cushion  defects 
 
Gastrointestinal  system 
• Duodenal  atresia 
• Omphalocele 
• Echogenic  bowel 
• Diaphragmatic  hernia 
 Genitourinary  system 
• Pylectasis 
• Multicystic  dysplastic kidney 
• Hydronephrosis 
 
Face 
• Harelip,  cleft  palate 
• Ocular  and  ear  anomalies 
• Abnormal  profile 
 
Limbs 
• Limb  length  discrepancy 
• Clubfoot 
• Rocker  bottom  foot 
• Sandal  toe 
• Simian Crease 
• Syndactyly 
 
 
 Miscellaneous 
• Cystic  hygroma 
• Non-immune  hydrops 
• IUGR 
• Abnormally  large placenta/small  placenta 
• Poly/oligohydramnios 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
  
 METHODOLOGY 
Design: 
 This  study  was  conducted  at  Coimbatore  Medical  College  
Hospital.  This  prospective  study  has  been  conducted  on  50  
pregnant  women,  between  10-14wks  of  gestation  with  regular  
menstrual  cycle  and  with  reliable  LMP  details  attending  the  
antenatal  Out  Patient Department  at  Coimbatore  Medical  College  
Hospital  during  a  period  of  1  year  from  August  2013 – August  
2014. 
Inclusion  criteria: 
• Study  of  50  pregnant  women  with  reliable  LMP  details. 
• Singleton  viable  intrauterine  pregnancy. 
Exclusion  Criteria: 
• Pregnant  women  with  unreliable  LMP  details 
• Multiple  pregnancies 
 
 
 
 
 
 
 
 Method: 
 The  patients  are  randomly  selected.  They  are  offered  
counseling  about  the  study  and  are  motivated  to  attend  Antenatal 
Outpatient  Department  at  the  specified  time  for  screening  and 
follow-up.  The  necessities  of  screening  at  each  trimester  were  
emphasized.  The  need  for  I  trimester  scan  to  diagnose  the  
viability,  to  detect multiple  pregnancy,  for  accurate  dating  of  
pregnancy,  to  assess  the  possibility  for  Down’s  Syndrome,  other  
chromosomal  abnormalities,  other  fetal  anamolies  by  measuring  
nuchal  translucency  were  explained. 
 
 The  importances  of  II  trimester  scan  at  20-22 weeks  to  
detect  fetal  structural  abnormalities,  growth  of  the  fetus  was  
explained.  The  cardiac  anamoly  detected  by  fetal  
echocardiography  done  at             22-24 weeks  was  explained.  After  
counseling  the  patient,  screening   was  offered  to  the  pregnant  
women. 
 
 
  The  patient’s  detailed  history  was  taken  and  any  risk  
factor  contributing  to  have  fetal  abnormality  was  noted.  Thorough  
clinical  examination  was  made.  General  examination  includes  
Blood  pressure,  pulse,  presence  of  pallor,  icterus,  pedel  edema.  
Systemic  and  obstetric  examination  was  made  in  detail.  
Preliminary  investigations  were  carried  out  at  10-14 weeks  scan,  
fetal  CRL,  NT,  any  obvious structural  anamoly  in  the  fetus,  
uterine  anamoly,  adnexa,  cervix  and  internal  os  were  noted. 
 
 After  the  scan,  the  estimated  risk  of   Down’s  syndrome  or  
other  fetal  abnormalities  are  discussed  with  the  patient  and  her  
family.  If  she  is  at  high  risk,  she  is  counselled  and  advised  to  
wait  for  the  target  scan  and  fetal  echocardiogram. 
 
1. In  target  scan,  fetus  is  examined  thoroughly  for  anamolies. 
 
2. Any  anamolies  present,  it  is  discussed  with  the  patient.  In  
trivial  pathology  and  correctable  disorder  patient  is  
counseled  and  advised  to  continue  the  pregnancy. 
 
 
 3. If  major  anamolies  are  present  in  the  patient  is  advised  for  
termination  of  pregnancy. 
 
Patient  is  followed  up  till  delivery,  adviced  for  institutional  
delivery.  If   NT  > 95
th
 centile  for  gestational  age,  she  was  
considered  to  be  at  high  risk. 
  
  
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
  
 RESULTS 
 A  prospective  clinical  study  consisting  of  50  pregnant  
women  is  undertaken  to  study  the  fetal  nuchal  translucency  at  
10-14 weeks  of  gestation  as  a  screening  tool  to  identify  fetal  
abnormalities.  
 
Table 1 
Age distribution 
Age in years Number % 
<20 4 8 
21-25 25 50 
26-30 17 34 
31-35 3 6 
>35 1 2 
  
 
 
  
 Most  of 
21-25 years (50%), 
between  <20  years,
>35 years. 
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Fig 25: Age distribution 
 the  pregnant  women  were 
 34%  were  between 26-30  years,
  6%  were  between  31-35 years and 2% were 
 
 
21-25 26-30 31-35 >35
Age
 
 between                             
  8% were 
Primigravida
Multigravida
 Primigravida
  
Multigravida
Table 2 
Gravida distribution 
Gravida Number % 
 28 56 
 22 44 
 
Fig 26: Gravida distribution 
  were  56%  and  Multigravida  were  44%.
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Gestational age in 
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Table 3 
Gestational age 
weeks 
Number 
(n=50) 
% 
11-12 9 18 
12.1-13 26 52 
13.1-14 15 30 
 
Fig 27: Gestational age 
  pregnant  women  were  scanned  between
 30 %   between 13.1-14 weeks  and  
-12 weeks. 
 
11-12 12.1-13 13.1-14
Gestational age in weeks
 
  12.1-
18%  were  
 Table 4 
Past obstetric history 
Past obstetric history Number % 
1.Nil 39 78 
2.Previous history of unexplained I trimester 
pregnancy loss 
4 8 
3.Previous history of unexplained term IUD 1 2 
4.Previous history of baby having anomalies 1 2 
5.Previous history of unexplained II trimester 
pregnancy loss 
2 4 
6.Previous history of preterm delivery 1 2 
7.Previous history of IUGR 1 2 
8.Previous history of GDM 2 4 
9.Previous history of GHT 1 2 
 
 One  patient  had  both  IUGR  and  GHT  in  previous  
pregnancy.  Another  patient  had  I  trimester  loss  and  GDM  in  
previous  pregnancy. 
 
 78%  of  pregnant 
the  past  obstetric  
 8%  of  
unexplained  I  trimester
 2%  of  
unexplained  II  trimester
 2%  of  
unexplained  term  
Fig 28: Past obstetric history 
 
 women  had  no  significant  risk
history. 
pregnant  women  had  previous  history
  pregnancy  loss. 
pregnant  women  had  previous  history
  pregnancy  loss. 
pregnant  women  had  pervious  history
IUD. 
  factors  in  
  of  
  of  
  of  
  2%  of  pregnant  women  had  pervious  history  of  baby  
having  anomaly. 
 2%  of  pregnant  women  had  pervious  history  of  preterm  
delivery. 
 2%  of  pregnant  women  had  pervious  history  of  IUGR. 
 4%  of  pregnant  women  developed  GDM  in  previous   
pregnancy. 
 2%  of  pregnant  women  developed  GHT  in  previous  
pregnancy. 
 
 
 
 
 
 
 
 
Risk factor in the present pregnancy identified at the time of NT 
Risk factor in the present pregnancy
1.Nil 
2.Overt Diabetic 
3.Previous LSCS 
4.Elderly Primi 
5.Hypothyroidism 
 
Fig 29: Risk factor in the present pregnancy identified at the time 
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Table 5 
scan 
 Number 
39 
1 
8 
1 
1 
of NT scan 
2 3 4
Risk Factor
% 
78 
2 
16 
2 
2 
 
5
  78%  of  pregnant  women   had no  risk  factor  at  the  time  of  
NT  scan.  2%  were  overt  diabetic,  16%  were  previous  LSCS  
cases,       2%  elderly  primi,  2%  had  hypothyroidism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 6 
Risk factors in the present pregnancy developed later 
Risk factor in the present pregnancy Number % 
1. Nil 26 52 
2. GDM 1 2 
3. PIH 6 12 
4. Postdated pregnancy 5 10 
5. Decreased liquor 3 6 
6. Breech presentation 1 2 
7. PROM 4 8 
8. PPROM 1 2 
9. Polyhydramnios 1 2 
10. IUGR 1 2 
11. Preterm labour 1 2 
 
 
 
 
 
Fig 30: Risk factors in the present pr
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Risk factors in the present pregnancy developed after 20 
weeks
egnancy developed later
  women  did  not  develop  any  risk
  women  developed  GDM. 
 women  developed  GHT. 
   went  in  for  postdatism. 
 women  developed  Oligohydramnios.
  women  had  breech  presentation. 
  women  developed  PROM. 
3 4 5 6 7 8 9 10
 
 
  factor. 
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 2%  of  pregnant  women  developed  PPROM. 
2%  of  pregnant  women  developed  polyhydramnios. 
2%  of  pregnant  women  developed  IUGR. 
2% of  pregnant  women  had  preterm  labour 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Nuchal Translucency
< 95
> 95
Fig 
 
96%  of  pregnant  
4% of  pregnant  women
Table 7 
Nuchal Translucency (NT) 
 Number %
th centile 48 96
th centile 2 4
 
31: Nuchal Translucency (NT) 
women  had  NT   less  than  95
th
 centile.
  had  NT  more  than  95
th
 centile. 
 
 
 
 
 
 Table 8 
Association of increased NT (> 95th centile) with fetal 
abnormalities 
Fetal abnormalities Increased NT 
(n=2) 
1.Trisomy 21 - 
2. Trisomy 18 - 
3.Trisomy 13 - 
4.Cardiac defects 1(50%) 
5.Pulmonary defects - 
6.Abdminal wall defects - 
7.Skeletal defects* - 
8.Genetic syndromes - 
9. Fetal loss - 
 
 
 
 
 
Fig 32: Association of increased NT (> 95th centile) with fetal 
 Out  of  the  two  mothers  with  increased  NT  one  of  the  
baby  had  cardiac  defect(50%),  other  baby  was  normal. 
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Mode
Caesarean Section
Vaginal delivery
 66%   of  pregnant
section  was  done  
 
 
Vaginal delivery
66%
Table 9 
Mode of delivery 
 Number % 
 17 34 
 33 66 
 
Fig 33: Mode of delivery 
  women  delivered  vaginally  and 
in  34%. 
Caesarean Section
34%
Mode of Delivery
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Table 10 
Birth weight 
 Number %
≤2.0 2 4 
2.1-2.5 4 8 
2.6-3.0 29 58
3.1-3.5 13 26
>3.5 2 4 
 
Fig 34: Birth weight 
had  birth  weight  between  2.6-
  3.1-3.5 kgs,  8%  between  2.1-2.5 kgs,
 and  4%  weighed ≤ 2 kgs. 
≤2.0 2.1-2.5 2.6-3.0 3.1-3.5 >3.5
Birth Weight in Kgs
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NICU admission
Preterm
 8%  of  babies
were  due  to  MAS,
IUGR  and  2%  were
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Table 11 
NICU Admission 
 Number % 
IUGR 1 2 
MAS 1 2 
 1 2 
CHD 1 2 
 
Fig 35: NICU Admission 
  needed  NICU  admission  out  of  which
  2%  were  due  to  preterm,  2%  were 
  due  to  Congenital  heart  disease (CHD).
IUGR MAS Preterm CHD
admission
 
  2%  
 due  to  
 
 Table 12 
Diagnostic value of increased NT in relation to fetal abnormalities 
 
Diagnostic value of NT Number 
True Positives 1 
True Negatives 47 
False Negative 1 
False Positive 1 
Sensitivity(%) 50.00% 
Specificity(%) 97.92% 
PPV(%) 50.00% 
NPV 97.92% 
p value 0.017 
 
 
 
 
 
Fig 36: Diagnostic value 
 Fetal  abnormalities
   p = 0.017 
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DISCUSSION 
  
 DISCUSSION 
 Antenatal  screening  of  nuchal  translucency  at  10-14 weeks  
of gestation  is  done  for  identification  of  fetal  anamolies  at  the  
earliest. 
 
 There  are  various  methods  of  screening  for  fetal  anamoly  
such  as  I trimester  scan, II  trimester  anamoly  scan, fetal  
echocardiography, maternal  serum  markers  and  invasive  testing  
like  cordocentesis,  celocentesis,  CVS,  aminocentesis.   
 
 The  ideal  test  for  all  pregnant  mothers  should  be  non-
invasive,  less  expensive  and  should  give  reliable  information  at  
the   earliest  regarding  the  fetal  anamoly,  so  that  the  affected  
women  would  be  offered  an  early  option  of  termination  of  
pregnancy.  The  screening  test  should  not  affect  the  fetus  and  the  
pregnant  mothers  and  should  not  cause  fetal  loss. Invasive  
methods  are  associated  with  fetal  loss  and  fetal  limb  reduction  
defects  which  causes  mental  trauma  to  the  pregnant  mothers.   All  
the  above  conditions  of  an  ideal  screening  test  is  fulfilled  by  
Nuchal  Translucency. 
  Nuchal  translucency  increases  with  increasing  gestational  
age.  It  is  measured  by  ultrasonogram  and  interference  is  made  
correspondingly.  Any  value  of  nuchal  translucency  >95
th
  centile  
for  the  gestational  age  is  increased  nuchal  translucency. 
 
 In  this  study  majority  of  the  women  were  between  21-25 
years(50%),  34%  were  between  26-30 years.  56%  were  
primigravida  and  44%  were  multigravida.  Most  of  the  women  
were  screened  between  12-13 weeks(52%),  30%  were  screened  
between  13-14 weeks,  18%  were  screened  between  11-12 weeks. 
 
 22%  of  pregnant  women  had  significant  past  obstetric  
complications  like  I and  II  trimester  loss,  IUD,  preterm  delivery,  
IUGR,  GDM,  GHT,  anamolous  baby.  Rest  of  the  pregnant  
women  had  no  previous  obstetric  complication.   
 
 48  pregnant  women  in  our  study(96%)  had  normal  NT  
valve(<95
th
 centile).  2  of  the pregnant  women  in  our  study(4%)  
had  increased  NT  valve(>95
th
 centile). All  the  women  under  study  
were  followed  with  Anamoly  scan  and  fetal  echocardiography.  
 Among  the  2  pregnant  women  with  increased  NT,  one  of  the  
baby  had  isolated  cardiac  defect(ASD)  and  the  pregnancy  was  
continued.  Other  baby  had  no  anamoly  in  the  follow-up  scan  and  
the  pregnancy  was  continued.  This  contributes  to  false  positive.  
 
 Among  the  48  pregnant  women  with  normal  NT,  one  of  
the  baby   had  Patent  ductus  arteriosus. Rest of   babies  were  
normal. Increased  NT  identifies  the  group  at  risk  not  only  for  
chromosomal  abnormalities   but  also  for  major  cardiac  defects.  
Our  study  needed  a  specialist  for  NT  measurement  and  fetal  
echocardiography.  Now  a  days  there  are  advanced  uitrasound  
machines  in  which  detailed    cardiac  scanning  is  possible  even  in  
I  trimester  of  pregnancy. 
 
 In  our  study  50%  of  major  cardiac  abnormalities  are  
associated  with  increased  NT  measured  at  10-14weeks  of  
gestation.  No  fetal  aneuploidy  was  detected  in  our  study,  as  the  
study  population  was  only  50  and  the  incidence  of  Down  
syndrome  is  1 in 600-700. 
  In  spite  of  NT,  I  trimester  ultrasonogram  is  also  used  to  
confirm  fetal viability,  accurate  dating  of  pregnancy,  early  
diagnosis  of  multiple  pregnancy  and  detection  of major  structural  
anamolies,  condition  of  uterus,  adnexa  and  cervical  length. 
 
 NT  measurement  done  in  I  trimester  was  traditionally  used  
for  fetal  aneuploidy  but  also  identifies  major  cardiac  defects,  
skeletal  defects  and  other  structural  defects.  The  decision  for  
termination  can  be  made  from  the  non-invasive  testing  itself.  If  
NT  is  increased,  other  sonographic  markers  of  screening  in  I  
trimester  along  with  maternal  serum  markers  can  be  done.  If  still  
patient  is  in  high  risk  group,  termination  can  be  opted.  NT  
measurement  combined  other  sonographic  markers  would  be  ideal  
consideration  for  I  trimester  termination.  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
  
 CONCLUSION 
1. NT  measurement  is  a  non  invasive,  reliable  screening   tool  
available  in  the   I  trimester  to  determine  the  fetus  at  risk  
for  fetal  aneuploidy,cardiac  defects,  structural  defects,  
genetic  syndromes. 
2. NT measurements  in  I  trimester  has  pushed   the  prenatal  
screening  for  fetal  anomalies  from  II  trimester   to  the  I  
trimester. 
3. Apart  from  Nuchal  Translucency,   I  trimester  ultrasonogram  
is  also  used  to  confirm  fetal viability,  accurate  dating  of  
pregnancy,  early  diagnosis  of  multiple  pregnancy  and  
detection  of major  structural  anamolies,  condition  of  uterus,  
adnexa  and  cervical  length. 
4.   Normal  fetal  NT  in  I  trimester  reassures  the  pregnant  
women  that  her  fetus  is  not  at  high  risk  for  fetal  
anamolies. 
5. Measurement  of  normal  NT  reduces  the  number  of  invasive  
procedures  like  CVS,  aminocentesis  and  cordocentesis 
6. Measurement  of  increased  NT  provides  women  with  
affected  fetuses  an  early  termination  option. 
 7. Increased  Nuchal  Translucency  identifies  the  women  at  risk  
group  and  should  be  followed  up  carefully  with  other  
screening  modalities. 
8. The  number  of  pregnant  women  were  only  50.  Study  
should  continue  with  large  number  of  patients  to  formulate  
a  definitive  protocol. 
  
  
 
 
 
 
 
 
 
 
 
 
SUMMARY 
  
 SUMMARY 
 It  is  a  prospective  clinical  study,  50  pregnant  women  were  
selected  randomly  between  10-14weeks  of  gestation  over  a  period  
of  one  year,  attending  the  antenatal  out-patient  department  of  
obstetrics  and  gynaecology  at  Coimbatore  Medical  College  
Hospital. 
 Screening  for  fetal  NT  was  performed  for  all  the 50  
pregnant  women  between  10-14weeks  of  gestation.  NT>95
th
 centile  
are  considered  as  screen  positive.  They  are  considered  to  be  at  
high  risk  for  fetal  anamolies.  All  the  women  with  normal  or  
increased  NT  were  followed  up  with  anamoly  scan  at  20-
22weeks  of  gestation  and  with  2-D  fetal  echocardiography  at  22-
24weeks  of  gestation. 
The  outcome  of  increased  NT  was  predicted  with  anamoly  
scan  and  fetal  echocardiography.  Statistical  analysis  was  carried  
out  to  test  the  significance  of  fetal  anamolies  in  relation  to  
increased  NT  and  to  find  the  diagnostic  value. 
In  our  study  50%  of  women  were  between  21-25  years,  
34%  were  between  26-30  years,  8%  were  <20  years,  6%  were  
between  31-35  years  and  2%  were  >35  years. 
 Although  the  risk  of  trisomy  21  is  increased  after  the  age  
of  35,  80%  of  down’s  babies  were  born  to  women  under  the  age  
of  35.  So  all  women  in  reproductive  age  group  are  included  in  
this  study.  The  screen  positive  value  of  NT  is  >95
th
 centile  which  
was  present  in  this  study  between the  age  of  26-30  years. 
In  this  study  56%  were  primigravida,  44%  were  
multigravida. 
In  this  study  NT  scan  were  performed  mostly  at  the  
gestational  age  of  12.1-13  weeks(52%),  30%  done  at  13.1-14  
weeks  of  gestation,  18%  at  11-12  weeks  of  gestation. 
Any  significant  risk  factor  in  the  past  pregnancy  was  
considered  and  22%  had  significant  obstetric  illness  in previous  
pregnancies. 
48  pregnant  women  in  our  study(96%)  had  normal  NT  
value(<95
th
 centile).  2  of  the pregnant  women  in  our  study(4%)  
had  increased  NT  value(>95
th
 centile).  Among  the  2 pregnant  
women  with  increased  NT,  one  of  the  baby  had  isolated  cardiac  
defect(ASD)  and  the  pregnancy  was  continued.  Other  baby  had  
no  anamoly  in  the  follow-up  scan  and  the  pregnancy  was  
continued.  This  contributes  to  false  positive.  
  Among  the  48  pregnant  women  with  normal  NT,  one  of  
the  baby   had  Patent  ductus  arteriosus. Rest of   babies  were  
normal. 
The  sensitivity  of  fetal  nuchal  translucency  >95
th
 centile  
used  for  screening  anamolies  is  50%,  specificity  is  97.92%,  
positive  predictive  value  is  50%,  negative  predictive  value  is  
97.92%  and  the  p  value  is  0.017.  Fetal  anamolies  are  
significantly  related  to  increased  value  of  nuchal  translucency.  
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ANNEXURES 
  
 PROFORMA 
Name: 
Age: 
Husband’s Name: 
Address: 
O. P. No: 
Education: 
Occupation: 
Monthly Income: 
PRESENTING COMPLAINTS: 
OBH: ML   Consanguinous/Non- Consanguinous      G     P     L     A 
 
Sl. No. Year Pregnancy 
outcome 
Delivery 
outcome 
Baby 
outcome 
     
     
     
     
 
H/O Previous Unexplained Fetal/Neonatal Death 
H/o Congenital Anomalies In The Previous Child 
 MH:   AOM 
 CYCLES-REGULAR 
PAST HISTORY 
Any H/o Congenital defects in the mother 
H/o DM /HTN / TB/ Epilepsy /Asthma/ Prev. surgery / Allergy to drug 
FAMILY HISTORY 
H/o any congenital anomalies / Mental Retardation in both the families. 
H/o Unexplained Fetal / Neonatal Death/ Recurrent Pregnancy Loss 
GENERAL PHYSICAL EXAMINATION 
Pallor / Icterus / Edema / Clubbing / Cyanosis / Lymphadenopathy 
PR                         BP 
Ht                         Wt 
Breast          Thyroid 
SYSTEMIC EXAMINATION 
CVS 
RS 
CNS 
OBSTETRIC EXAMINATION 
Sl. No.         Date         WT  BP  P/A   P/V 
 
 
 INVESTIGATIONS 
A. Routine:                                                     
     Hb%             HIV    BT 
     PCV         HbsAg   CT 
     Urine Routine        VDRL 
     Blood Group and RH Typing      RBS 
  
B. ULTRASOUND 
1. 10-14 weeks scan 
Gestation Sac    Gestation Age 
CRL     Both Adnexa 
Anomalies    NT  
         
2. IF NT INCREASED OR NORMAL → II TRIMESTER SCAN AND 
FETAL ECHOCARDIOGRAPHY DONE 
3. II TRIMESTER SCAN: 
BPD      GESTATION AGE 
HC      FHR 
AC      PLACENTA  
FL      EFW 
EDD 
CONGENITAL ANOMALIES 
 4. FETAL ECHO 
IF IN II TRIMESTER SCAN 
•NO CONGENITAL ANOMALIES DETECTED → CONTINUATION OF 
PREGNANCY 
•LETHAL CONGENITAL ANOMALIES → TERMINA TION 
  
5.III TRIMESTER SCAN: 
BPD      EFW 
FL      PLACENTA 
HC      FHR 
AC      AFI 
GESTATION AGE    PRESENTATION 
EDD 
Nature of delivery 
INDUCTION  *  INDICATION 
  *   METHOD 
SPONTANEOUS 
MODE OF DELIVERY: 
• VAGINAL 
• ABDOMINAL 
UMBILICAL CORD / PLACENTA 
  
 
EVALUATION OF BABY BY PAEDIATRICIAN: 
SEX 
WT 
DOB 
TOB 
APGAR 
ANY CONGENITAL ANOMALIES / CARDIAC DEFECTS 
PERINATAL MORTALITY 
 
  
 CONSENT FORM 
 
Here by I volunteer and to participate in this study  
“A   STUDY   OF   NUCHAL  TRANSLUCENCY  IN  
EARLY  PREGNANCY”  was fully explained about the 
nature of this study by the doctor, knowing which I 
Mr/Mrs________________________ fully consent to 
volunteer in this study. 
 
 
Date: 
Place:                                      Signature of the Volunteer 
                    
 
 
 
 
 
  
 xg;g[jy;  gotk;; [ ; ;; [ ; ;; [ ; ; 
bgah; : 
ghypdk; :        taJ : 
Kfthp : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; kfg;ngW kUj;Jt 
Jiwapy; gl;l gapYk; khztp mth;fs; nkw;bfhs;Sk; "gpwf;fg; 
nghFk; FHe;ijf;F gpwtpf; FiwghL cs;sjh vd;gij mwpa[k; 
epa{f;fs; onud;!;Yrd;rp vd;Dk; !;nfd; mstPL" Fwpj;j 
Ma;tpy; bra;Kiw kw;Wk; midj;J tptu';fisa[k; nfl;Lf; 
bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; 
vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; 
btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; 
bfhs;fpnwd;. ve;j neuj;jpy; ,e;j Ma;tpypUe;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk;  :        ifbahg;gk;  
ehs; : 
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 KEY TO MASTER CHART 
G   → Gravida 
P   → Parity 
L   → Live child 
A   → Abortion 
DM   → Diabetes mellitus 
GHT   → Gestational Hypertension 
Prev   → Previous 
LSCS   → Lower segment cesarean section 
PROM  → Prelabour rupture of membranes 
PPROM  → Preterm prelabour rupture of membranes 
LN   → Labour Natural 
AVD   → Assisted Vaginal Delivery 
VBAC  → Vaginal Birth After Cesarean 
PTB   → Preterm Birth 
IUD   → Intrauterine Death 
IUGR   → Intra uterine growth restriction 
MAS   → Meconium Aspiration syndrome 
LBW   → Low birth weight 
CHD   → Congenital heart disease 
ASD   → Atrial septal defect 
PDA   → Patent ductus arteriosus 
 
